Mode
Text Size
Log in / Sign up
Phase 4 Completed N=5 Supportive Care

Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients

Source: ClinicalTrials.gov NCT00998426 ↗
Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcomePrimary: Differences in Blood Glucose Levels as Measured by GNS-POC, GS-POC and Venous Blood Prior to and After HBIG Injection — -3.2; 6.0; 56.6; -2.6 mg/dL — p=0.59

Summary

HepaGam B Hepatitis B Immune Globulin (HBIG) solution contains 10% maltose, which could possibly interfere with the measurement of glucose levels when using glucose non-specific tests. The purpose of this study is to determine whether use of HepaGam B HBIG shows an increase in glucose levels in the body using non-specific glucose monitoring, as well as specific glucose monitoring. The sponsor believes that this medication will not cause a significant increase in glucose levels in the body when measured by glucose non-specific tests.

Outcome Measures

OutcomeResultp-value
PRIMARY
Differences in Blood Glucose Levels as Measured by GNS-POC, GS-POC and Venous Blood Prior to and After HBIG Injection
-3.2; 6.0; 56.6; -2.6; 7.4; 10.6 0.59

Eligibility Criteria

Inclusion Criteria

  • written informed consent
  • HBsAG positive candidates for HBV related liver transplant to be placed on HepaGam B therapy for the prevention of HBV recurrence in both the acute phase (immediately post operative) and the long term maintenance phase
  • at least 18 years of age

Exclusion Criteria

  • unable or unwilling to provide written informed consent
  • concomitant administration of other maltose containing products such as dietary supplements, dietary aids, IVIG, external peritoneal dialysis solution in both arms
  • concomitant administration of corticosteroids in the long term maintenance phase
  • pregnancy, as determined by a pregnancy test administered after consent has been signed
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00998426). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search